Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries UroGen Pharma to Participate at Upcoming Investor Conferences By: UroGen Pharma Ltd. via Business Wire May 07, 2024 at 08:00 AM EDT – Citizens JMP Life Sciences Conference – – H.C. Wainwright 2nd Annual BioConnect Conference – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: May 20, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507449972/en/Contacts INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093 MEDIA CONTACT: Cindy Romano Director, Corporate Communications cindy.romano@urogen.com 609-460-3583 ext. 1083 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
UroGen Pharma to Participate at Upcoming Investor Conferences By: UroGen Pharma Ltd. via Business Wire May 07, 2024 at 08:00 AM EDT – Citizens JMP Life Sciences Conference – – H.C. Wainwright 2nd Annual BioConnect Conference – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: May 20, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507449972/en/Contacts INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093 MEDIA CONTACT: Cindy Romano Director, Corporate Communications cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: May 20, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507449972/en/
INVESTOR CONTACT: Vincent Perrone Senior Director, Investor Relations vincent.perrone@urogen.com 609-460-3588 ext. 1093 MEDIA CONTACT: Cindy Romano Director, Corporate Communications cindy.romano@urogen.com 609-460-3583 ext. 1083